Ocugen (NASDAQ:OCGN – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Ocugen to related businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.
Profitability
This table compares Ocugen and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ocugen | N/A | -127,987.80% | -115.95% |
| Ocugen Competitors | -9,054.31% | -198.21% | -30.53% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Ocugen and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ocugen | 1 | 0 | 4 | 0 | 2.60 |
| Ocugen Competitors | 9770 | 15029 | 45237 | 1570 | 2.54 |
Ocugen presently has a consensus price target of $9.50, indicating a potential upside of 1,251.93%. As a group, “Biotechnology” companies have a potential upside of 95.47%. Given Ocugen’s stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than its peers.
Institutional and Insider Ownership
10.3% of Ocugen shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Ocugen and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Ocugen | $4.41 million | -$67.85 million | -2.70 |
| Ocugen Competitors | $737.75 million | $13.23 million | -10.05 |
Ocugen’s peers have higher revenue and earnings than Ocugen. Ocugen is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Ocugen has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. Comparatively, Ocugen’s peers have a beta of 1.02, meaning that their average stock price is 2% more volatile than the S&P 500.
Summary
Ocugen peers beat Ocugen on 7 of the 13 factors compared.
About Ocugen
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
